- November 22, 2026
- Updated 8:26 am
Disappointing Results for Heart Drug in Preventing Attacks
- 29 Views
- admin
- November 7, 2026
- Health Medical Research
An experimental drug designed to prevent heart attacks and strokes failed a critical test, as reported by researchers on Saturday. Intended to lower a blood particle linked with heart issues, the medication didn’t protect participants in a key study.
Unexpected Outcome
“I was shocked. I had high hopes for success,” remarked Steven Nissen, a cardiologist at the Cleveland Clinic who led the study. Cardiovascular disease remains the top cause of death in developed countries. Researchers aimed to find therapies reducing risks for those managing their cholesterol and blood pressure, eating well, maintaining a healthy weight, and exercising. Despite these efforts, many still encounter heart attacks and strokes.
Focus on Lipoprotein(a) or Lp(a)
Many affected individuals have higher blood levels of lipoprotein(a) or Lp(a), a protein thought to increase heart disease risk. “About 20% of the global population has elevated levels. That’s around a billion people,” Nissen noted. Until recently, no drugs effectively lowered Lp(a). Recent years saw the development of experimental medications aiming to reduce elevated Lp(a).
Study and Results
Nissen and his team administered a placebo or the drug pelacarsen, known to cut Lp(a), to 8,350 adults already with heart disease. The drug successfully suppressed Lp(a) by about 78%. However, after five years, the reduction didn’t translate into fewer cardiovascular complications.
“Very disappointing, terribly disappointing,” Nissen commented. He presented the study details at an American Heart Association meeting and published specifics in the New England Journal of Medicine.
Novartis, the study’s sponsor, had previously announced that the results didn’t meet expectations. The company stated the study offers “meaningful evidence” on Lp(a) and heart disease, potentially informing future cardiovascular management approaches.
Understanding the Failure
The failure is surprising, given hopes in the scientific community for Lp(a)-lowering drugs as a significant advancement against cardiovascular diseases. “I think it’s a big deal,” said Harlan Krumholz, a Yale University cardiologist.
Researchers are unsure what went wrong. Possibilities include high Lp(a) being a risk marker rather than a cause, or requiring longer or earlier treatment. Another theory suggests drugs may only aid those with higher Lp(a) levels.
Additional factors could be that Lp(a)-lowering drugs may help those with less controlled blood pressure and cholesterol. Alternatively, something specific to pelacarsen might explain the lack of benefit.
Other drugmakers like Amgen and Eli Lilly continue testing alternative Lp(a)-lowering drugs. Results from these studies are anticipated in the coming years.
“The take-home message is the story’s not over,” said Karol Watson, a cardiologist at the University of California, Los Angeles. “It’s kind of just starting.”